The company has established several strategic collaborations, licensing, and supply agreements with various organizations. These include a Clinical Study Collaboration and Supply Agreement with Gilead Sciences, Inc., Clinical Trial Collaboration and Supply Agreements with Pfizer Inc., and License Agreements with Novartis, Cancer Research Technologies Ltd., the University of Manchester, Biocytogen ii Pharmaceuticals (Beijing) Co. Ltd., Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servier. These agreements pertain to the manufacture and supply of companion diagnostics and product candidates.
Ideaya Biosciences Inc's Comment on Supply Chain
The company has established several strategic collaborations, licensing, and supply agreements with various organizations. These include a Clinical Study Collaboration and Supply Agreement with Gilead Sciences, Inc., Clinical Trial Collaboration and Supply Agreements with Pfizer Inc., and License Agreements with Novartis, Cancer Research Technologies Ltd., the University of Manchester, Biocytogen ii Pharmaceuticals (Beijing) Co. Ltd., Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servier. These agreements pertain to the manufacture and supply of companion diagnostics and product candidates.
Sources:
Ideaya Biosciences Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Ideaya Biosciences Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
